Drug class profile · refreshed daily from federal data

Partial Opioid Agonist

3 molecules in this class, $536.9M combined CY2024 Part D spend across 1.7M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Partial Opioid Agonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $536.9Mcombined across class
Total Rx claims: 1.7M350K unique beneficiaries
Generic mfrs (active): 15across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Buprenorphine

Brand: BELBUCA · 1.7M Part D claims (CY24) · 350K beneficiaries · First FDA approval: 2005-05-25

15 generic mfrs 631 plans require PA

Low NADAC$0.263

→

Avg plan cost$26.72

Part D spend $536.9M 102× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Buprenorphine and Naloxone

Brand: Buprenorphine HCl and Naloxone HCl · — Part D claims (CY24) · First FDA approval: 2013-02-22

Brand-only (no generics) 0 plans require PA

Low NADAC$0.412

→

Avg plan cost$3.06

Part D spend — 7× spread, current vs floor

Class share

of class CY24 spend

View profile →

Buprenorphine and Naloxone Hydrochloride

— Part D claims (CY24) · First FDA approval: 2014-06-27

Brand-only (no generics) 0 plans require PA

Low NADAC$0.412

→

Avg plan cost$0.541

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.